Royalty Pharma plc (RPRX) is listed on NASDAQ in Pharmaceutical Stocks. It is $60.85, -1.73%, with a $26.8B market cap. RSI is 58.2, neutral. The latest reported quarter beat estimates. Insiders were net sellers across the listed trades.
Technical Analysis
RSI (14) 58.2 Neutral
Market Cap $26.8B
P/E Ratio 85.7x
Volume 1.3M
Fundamentals — 10-Q Q2 2026
Revenue $1.3B
Net Income $312.6M
EPS $0.71
Operating Margin 53.4%
Net Margin 24.0%
Debt / Equity 0.9x
P/E Ratio 85.7x
Earnings
Recent Insider Trades
| Name | Title | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|---|
| Hite Christopher | EVP & Chairman, Partnering | Sell | 100,000 | $59.97 | $6.0M | 2026 Aug 18 |
| Coyne Terrance P. | EVP & CFO | Sell | 11,002 | $58.68 | $645,551 | 2026 Aug 13 |
| Urist Marshall | EVP, Research & Investments | Sell | 9,099 | $55.88 | $508,454 | 2026 Jul 1 |
| Hite Christopher | EVP & Chairman, Partnering | Sell | 130,000 | $56.50 | $7.3M | 2026 Jun 30 |
| Urist Marshall | EVP, Research & Investments | Sell | 9,098 | $55.18 | $502,067 | 2026 Jun 24 |
| Hite Christopher | EVP & Chairman, Partnering | Sell | 150,000 | $54.40 | $8.2M | 2026 Jun 23 |
| Coyne Terrance P. | EVP & CFO | Sell | 64,399 | $53.98 | $3.5M | 2026 May 26 |
| Urist Marshall | EVP, Research & Investments | Sell | 13,684 | $52.75 | $721,838 | 2026 May 20 |
| Urist Marshall | EVP, Research & Investments | Sell | 13,684 | $53.06 | $726,137 | 2026 May 14 |
| Norden Gregory | Director | Sell | 3,045 | $53.00 | $161,385 | 2026 May 14 |
| Coyne Terrance P. | EVP & CFO | Sell | 34,791 | $49.78 | $1.7M | 2026 Apr 28 |
| Coyne Terrance P. | EVP & CFO | Sell | 34,791 | $48.33 | $1.7M | 2026 Apr 1 |
| Coyne Terrance P. | EVP & CFO | Sell | 34,791 | $45.53 | $1.6M | 2026 Mar 23 |
| Coyne Terrance P. | EVP & CFO | Sell | 34,791 | $46.78 | $1.6M | 2026 Mar 2 |
| Coyne Terrance P. | EVP & CFO | Sell | 34,791 | $45.32 | $1.6M | 2026 Feb 23 |
| Urist Marshall | EVP, Research & Investments | Sell | 20,000 | $39.32 | $786,400 | 2025 Dec 26 |
| Urist Marshall | EVP, Research & Investments | Sell | 20,000 | $38.38 | $767,600 | 2025 Dec 19 |
| Lloyd George W. | EVP, Investments & CLO | Sell | 110,000 | $38.55 | $4.2M | 2025 Dec 18 |
| Urist Marshall | EVP, Research & Investments | Sell | 20,000 | $38.32 | $766,400 | 2025 Dec 16 |
| Coyne Terrance P. | EVP & CFO | Sell | 69,582 | $38.36 | $2.7M | 2025 Dec 15 |
Other Pharmaceutical Stocks
| Ticker | Price | RSI | Mkt Cap |
|---|---|---|---|
| | $1,173.34 | 46.3 | $1.1T |
| | $268.01 | 58.6 | $645.9B |
| | $148.31 | 64.1 | $365.9B |
| | $50.83 | 49.4 | -- |
| | $118.52 | 47.9 | $25.9B |
| | $13.17 | 50.0 | $2.7B |
| | $113.32 | 33.7 | -- |
Take RPRX further
- Browse Pharmaceutical Stocks for the rest of the group, with what the businesses in it have in common and where they differ.
- Put RPRX in a portfolio and see what it does to total return, drawdown, and how the rest of your holdings move with it. Compares against the S&P 500 over the same days, free and without an account.
- Screen for others like it by RSI, valuation, market cap, and insider activity.
- Check the earnings calendar for when Royalty Pharma plc next reports.
Set alerts on RPRX
Get notified when Royalty Pharma plc hits your price targets or technical conditions are met.
Get Started Free